Daix (France), Long Island City (New York, United States), July 28, 2022 – Inventiva (EuronextParisandNasdaq:IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today reported its cash position as of June 30, 2022, and its revenues for the first half of 2022.
Read more at globenewswire.comInventiva Reports 2022 First-Half Financial Information¹
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/AI%20(artificial%20intelligence)/Image%20of%20server%20racks%20in%20modern%20server%20room%20data%20center%20by%20Sashkin%20via%20Shutterstock.jpg)
